Key facts
- It has raised $130.5M; the latest was Later Stage VC ($78.0M) in Oct 2024.
- Notable investors include Sequoia Capital, Keiretsu Forum, Catalio Capital Management, Johnson & Johnson JJDC, Arboretum Ventures — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Orasis Pharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Orasis Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Orasis Pharmaceuticals
Operator of an ophthalmic pharmaceutical company intended to develop corrective eye drops for the treatment of presbyopia. The company's eye drop improves near-uncorrected visual acuity and relieves presbyopia symptoms to eliminate the need for reading glasses, enabling patients with presbyopia to avail of non-invasive treatment options for improving their vision.
- Sector
- Healthcare
- HQ
- Ponte Vedra Beach, FL, United States
- Founded
- 2015
- Employees
- 87
- Website
- orasis-pharma.com/
- Ownership
- Privately Held (backing)
Orasis Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Orasis Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Orasis Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.